MONTREAL, CANADA--(Marketwired - May 24, 2013) - Theratechnologies Inc. (TSX:TH) today held its annual meeting of shareholders, chaired by Paul Pommier, chairman of the board of Theratechnologies.
At the meeting, the following people were elected as company directors by a majority of the votes.
| FOR | % FOR | ABSENTION | % ABSTENTION | |
| Gilles Cloutier | 16,493,771 | 93.63 | 1,122,061 | 6.37 |
| Gérald A. Lacoste | 15,977,261 | 90.70 | 1,638,571 | 9.30 |
| Dawn Svoronos | 17,138,172 | 97.29 | 477,660 | 2.71 |
| Jean-Denis Talon | 16,492,371 | 93.62 | 1,123,461 | 6.38 |
| Luc Tanguay | 17,018,571 | 96.61 | 597,261 | 3.39 |
| Paul Pommier | 16,488,369 | 93.60 | 1,127,463 | 6.40 |
At the meeting, the shareholder rights plan was renewed, and KPMG was appointed as auditors of the Corporation.
Appointment of new chairman
Immediately after the meeting, the board members met to appoint Dawn Svoronos as the new chair of the board, as previously announced.
They also confirmed Luc Tanguay as president and CEO of Theratechnologies.
About Theratechnologies
Theratechnologies (TSX:TH) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on the Securities and Exchange Commission website at www.sec.gov.
Contact Information:
NATIONAL Public Relations
514-843-2393